As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Celularity Inc. The largest reported stake is Dragasac Limited's, at 41%. 7 filings are on record since July 28, 2025 (Schedule 13D/A, July 28, 2025).
Sell to companies like Celularity Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Philip & Daniele Barach Family Trust · Sole voting: 0 · Shared voting: 11,940,187 · Sole dispositive: 0 · Shared dispositive: 11,940,187 · SCHEDULE 13D/A, 2026-09-28
- · Holder: Philip & Daniele Barach Family Trust · Percent: 15.8% · SCHEDULE 13D/A
- · Holder: Philip & Daniele Barach Family Trust · Percent: 20.1% · SCHEDULE 13D/A
- · Holder: Philp & Daniele Barach Family Trust · Percent: 9.56% · SCHEDULE 13D
- · Holder: Lincoln Alternative Strategies LLC · Percent: 0% · SCHEDULE 13G/A
Celularity Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-28. 2 holders' latest filing reports 5% or more of class a common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Dragasac Limited | 41% | 6,335,630 | SCHEDULE 13D/A, 2025-07-28 | 2025-07-24 |
| Philip & Daniele Barach Family Trust | 29% | 11,940,187 | SCHEDULE 13D/A, 2026-09-28 | 2026-09-23 |
| Lincoln Alternative Strategies LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-11 | 2025-07-14 |
Holding shares or following this stake? See who's behind Celularity Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Celularity Inc. and the records around it.
Celularity Inc. elsewhere on the record
- Leadership changes Aug 2026
- Form D filing Nov 2025
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026), Bionano Genomics, Inc. (Sep 2025)
Watch Celularity Inc.
Get an email when Celularity Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Celularity Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Celularity Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Celularity Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Philip & Daniele Barach Family Trust | 0 | 11,940,187 | 0 | 11,940,187 | SCHEDULE 13D/A, 2026-09-28 |
| Philip A. Barach | 0 | 11,940,187 | 0 | 11,940,187 | SCHEDULE 13D/A, 2026-09-28 |
| Daniele Barach | 0 | 11,940,187 | 0 | 11,940,187 | SCHEDULE 13D/A, 2026-09-28 |
The latest filing identifies Celularity Inc. by CUSIP 151190204 and gives its principal executive office as 170 PARK AVE, FLORHAM PARK, NJ 07932 (SCHEDULE 13D/A, 2026-09-28).
Purpose of Transaction (Item 4)
Dragasac Limited
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Pursuant to the terms agreed upon in the binding term sheet ("Term Sheet") between the Issuer and RWI dated February 12, 2025, RWI agreed to, among other things, an extension of that certain second forbearance agreement dated as of March 13, 2024. Specifically, RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the second amended and restated senior secured loan agreement dated as of January 12, 2024 until an amendment is entered into between the Issuer and RWI whereby the maturity date of the following loans is extended to February 15, 2026: (i) an initial loan in the aggregate principal amount of $6,000,000, (ii) a second loan in the aggregate principal amount of $6,000,000, and (iii) a third loan in the aggregate principal amount of $15,000,000, net of an original issue discount amount equal to $3,750,000. As agreed upon in the Term Sheet, on July 24, 2025, the exercise price of each of the following warrants was adjusted to $2.844 per Common Share, which represents a 10% discount from the closing price of the Issuer's Common Shares on July 24, 2025: (i) the RWI Warrant to purchase 300,000 Common Shares (as adjusted for the Reverse Stock Split) issued to RWI in June 2023, (ii) the Tranche 2 Warrants to purchase 1,350,000 Common Shares (as adjusted for the Reverse Stock Split) issued to RWI in January 2024, and (iii) the Forbearance Warrant to purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-28; the filing has the rest
Philip & Daniele Barach Family Trust
In connection with the Financing, on September 23, 2026, the Trust and the Company entered into a Board Rights Agreement, pursuant to which the size of the Company's board of directors is to be fixed at five directors, with the Trust having the right to designate two persons to be appointed to the board of directors (the "Trust Directors"). Philip Barach, a trustee of the Trust, was appointed to the Company's board of directors as a designee of the Trust under the Board Rights Agreement on September 24, 2026. In addition, the reasonable approval of the Trust Directors must be obtained for the appointment of an independent director by the other directors, and the Company's ability spend the proceeds received in the Financing will be limited until the Company's board of directors is composed of such persons as are required by the Board Rights Agreement. The Reporting Persons expect to evaluate on an ongoing basis the Company's financial condition and prospects and their interest in, and intentions with respect to, the Company and their investment in the securities of the Company, which review may be based on various factors, including the Company's business and financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Company's securities in particular, as well as other developments and other investment opportunities, which, if effected, could result in, among other things, any of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-28; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-28 | Dragasac Limited | 41% | SCHEDULE 13D/A |
| 2025-08-27 | Lincoln Alternative Strategies LLC | 5.14% | SCHEDULE 13G |
| 2026-02-11 | Lincoln Alternative Strategies LLC | 0% | SCHEDULE 13G/A |
| 2026-04-03 | Philp & Daniele Barach Family Trust | 9.56% | SCHEDULE 13D |
| 2026-04-22 | Philip & Daniele Barach Family Trust | 20.1% | SCHEDULE 13D/A |
| 2026-06-23 | Philip & Daniele Barach Family Trust | 15.8% | SCHEDULE 13D/A |
| 2026-09-28 | Philip & Daniele Barach Family Trust | 29% | SCHEDULE 13D/A |
Questions about who owns Celularity Inc.
Who owns Celularity Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Celularity Inc.: Dragasac Limited (41%, Schedule 13D/A, filed 2025-07-28) and Philip & Daniele Barach Family Trust (29%, Schedule 13D/A, filed 2026-09-28).
Who are the largest shareholders of Celularity Inc.?
By the share each holder's latest filing reports, the largest holders of Celularity Inc. on this page are Dragasac Limited (41%) and Philip & Daniele Barach Family Trust (29%).
When did Dragasac Limited buy into Celularity Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dragasac Limited on this page is the Schedule 13D/A, filed 2025-07-28, reporting 41%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Celularity Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 29, 2026 | Leadership change: Naveen Jain appointed, Director, and 2 more | — | Leadership changes | Source |
| September 28, 2026 | Leadership change: Philip A. Barach appointed, Director, and 1 more | — | Leadership changes | Source |
| August 7, 2026 | Leadership change: Rick Gonzalez departs, Chief Commercial Officer | — | Leadership changes | Source |
| June 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 25, 2026 | Leadership change: Steven N. Gordon appointed, Chief Operating and Administrative Officer, and 2 more | — | Leadership changes | Source |
| June 3, 2026 | Leadership change: Rick Gonzalez appointed, Chief Commercial Officer | — | Leadership changes | Source |
| April 21, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| November 3, 2025 | Form D, private offering | $2M sold | Form D page | Source |
| August 5, 2025 | Form D, private offering | $1.03M sold | Form D page | Source |
| August 5, 2025 | Form D, private offering | $6.81M sold | Form D page | Source |
| August 5, 2025 | Form D, private offering | $2M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Celularity Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.